Chromatin-remodeling complex SWI/SNF controls multidrug resistance by transcriptionally regulating the drug efflux pump ABCB1

Cancer Research

Volumn 76, Issue 19, 2016, Pages 5810-5821

  Dubey, Ramin ^a   Lebensohn, Andres M ^a   Bahrami Nejad, Zahra ^a   Marceau, Caleb ^a   Champion, Magali ^a   Gevaert, Olivier ^a   Sikic, Branimir I ^a   Carette, Jan E ^a   Rohatgi, Rajat ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; BRM PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN SWI; TRANSCRIPTION FACTOR SNF; ABCB1 PROTEIN, HUMAN; DNA HELICASE; MULTIDRUG RESISTANCE PROTEIN; NUCLEAR PROTEIN; SMARCA4 PROTEIN, HUMAN; SMARCB1 PROTEIN, HUMAN; SWI/SNF RELATED MATRIX ASSOCIATED ACTIN DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY B MEMBER 1; TRANSCRIPTION FACTOR;

ABCB1 GENE; ALLELE; ARID1A GENE; ARTICLE; CELL VIABILITY; CHROMATIN STRUCTURE; CONTROLLED STUDY; CRISPR CAS SYSTEM; DOWN REGULATION; DRUG SENSITIVITY; EPISTASIS; EXON; GAIN OF FUNCTION MUTATION; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INSERTION; GENETIC SCREENING; HAPLOIDY; HUMAN; HUMAN CELL; INTRON; LC50; LOSS OF FUNCTION MUTATION; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMARCB1 GENE; TADA3 GENE; TOP2A GENE; TRANSCRIPTION REGULATION; UPREGULATION; WILD TYPE; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG RESISTANCE; GENETIC TRANSCRIPTION; GENETICS; PHYSIOLOGY;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA HELICASES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HAPLOIDY; HUMANS; NUCLEAR PROTEINS; P-GLYCOPROTEINS; SMARCB1 PROTEIN; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84989899660     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-0716     Document Type: Article

References (37)

1. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41.
2. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17: 421-33.
3. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994;83:517-30.
4. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 2008;105:9053-8.
5. Dykhuizen EC, Hargreaves DC, Miller EL, Cui K, Korshunov A, Kool M, et al. BAF complexes facilitate decatenation of DNA by topoisomerase IIalpha. Nature 2013;497:624-7.
6. Wijdeven RH, Pang B, van der Zanden SY, Qiao X, Blomen V, Hoogstraat M, et al. Genome-wide identification and characterization of novel factors conferring resistance to topoisomerase II poisons in cancer. Cancer Res 2015;75:4176-87.
7. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455: 152-62.
8. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011;477:340-3.
9. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013;8:2281-308.
10. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 2014;11:783-4.
11. Carette JE, Guimaraes CP, Wuethrich I, Blomen VA, Varadarajan M, Sun C, et al. Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat Biotechnol 2011;29:542-6.
12. Carette JE, Guimaraes CP, Varadarajan M, Park AS, Wuethrich I, Godarova A, et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science 2009;326:1231-5.
13. Blomen VA, Majek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, et al. Gene essentiality and synthetic lethality in haploid human cells. Science 2015;350:1092-6.
14. Wang W, Cote J, Xue Y, Zhou S, Khavari PA, Biggar SR, et al. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J 1996;15:5370-82.
15. Phelan ML, Sif S, Narlikar GJ, Kingston RE. Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell 1999; 3:247-53.
16. Martinez E, Palhan VB, Tjernberg A, Lymar ES, Gamper AM, Kundu TK, et al. Human STAGA complex is a chromatin-acetylating transcription coactivator that interacts with pre-mRNA splicing and DNA damage-binding factors in vivo. Mol Cell Biol 2001;21:6782-95.
17. Wang YL, Faiola F, Xu M, Pan S, Martinez E. Human ATAC Is a GCN5/ PCAF-containing acetylase complex with a novel NC2-like histone fold module that interacts with the TATA-binding protein. J Biol Chem 2008;283:33808-15.
18. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56: 4171-9.
19. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339: 819-23.
20. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74-9.
21. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:203-6.
22. Roberts CWM, Galusha SA, McMenamin ME, Fletcher CDM, Orkin SH. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes tomalignant rhabdoid tumors in mice. Proc Natl Acad Sci U S A 2000;97:13796-800.
23. Roberts CWM, Orkin SH. The SWI/SNF complex - chromatin and cancer. Nat Rev Cancer 2004;4:133-42.
24. Wilson BG, Roberts CWM. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11:481-92.
25. Klochendler-Yeivin A, Fiette L, Barra J, Muchardt C, Babinet C, Yaniv M. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep 2000;1:500-6.
26. AbuHammad S, Zihlif M. Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics 2013;101:213-20.
27. Chi TH, Wan M, Zhao K, Taniuchi I, Chen L, Littman DR, et al. Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes. Nature 2002;418:195-9.
28. Tolstorukov MY, Sansam CG, Lu P, Koellhoffer EC, Helming KC, Alver BH, et al. Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci U S A 2013;110:10165-70.
29. Minderman H, Vanhoefer U, Toth K, Yin MB, Minderman MD, Wrzosek C, et al. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)- mediated drug efflux. Cytometry 1996;25:14-20.
30. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 2013;45:592-601.
31. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One 2013;8:e55119.
32. Masliah-Planchon J, Bieche I, Guinebretiere JM, Bourdeaut F, Delattre O. SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol 2015;10:145-71.
33. Chen KG, Sikic BI.Molecular pathways: Regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 2012;18:1863-9.
34. Wang X, Sansam CG, Thom CS, Metzger D, Evans JA, Nguyen PTL, et al. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res 2009;69:8094-101.
35. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. NatMed 2014;20:251-4.
36. Helming KC, Wang X, Roberts CW. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 2014;26:309-17.
37. Wilson BG, Helming KC, Wang X, Kim Y, Vazquez F, Jagani Z, et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol 2014;34:1136-44.